



EQA SOLUTIONS  
**SARS-COV-2 (COVID-19)**  
**ANTIGEN TESTING PILOT STUDY**

**RAN**OX

Randox is pleased to announce a new QCMD EQA pilot study for SARS-CoV-2 (COVID-19) Antigen Testing. This pilot is designed to evaluate a laboratories ability to detect SARS-CoV-2 (COVID-19) Antigen and will provide an opportunity to assess performance against an international peer group.

QCMD is a world leading EQA / Proficiency Testing (PT) provider, dedicated to improving the quality of diagnostic assays used in the detection of infectious diseases. With an extensive database of over 10,000 participants in over 100 countries, QCMD is one of the largest providers of EQA in the field of infectious disease testing.

---

## Benefits



### **SMART-PHONE APP RESULTS SUBMISSION**

Results can be returned via a new smart-phone app so that participants using Lateral flow devices can provide pictures of their device/result with the phone camera. The QCMD ITEMS web portal can also be used.



### **COMPREHENSIVE REPORTS**

A real-time, rapid report will be provided on submission of results. An individual report is received after each challenge, summarising laboratory performance in comparison to an international peer group.



### **ONLINE EQA MANAGEMENT SYSTEM**

IT EQA Management System (ITEMS) provides an online tool to easily manage all EQA activities from programme registration to submission of results and provision of EQA reports.



### **NOT INFECTIOUS**

Samples containing SARS-CoV-2 antigens are inactivated and not infectious ensuring safe handling of material.



### **SUITABLE FOR POINT OF CARE**

Samples are supplied liquid ready-to-use ensuring they are suitable for use at the point of care.

## EQA Pilot Study

### QCMD 2021 SARS-COV-2 ANTIGEN TESTING EQA PILOT STUDY (SCV2AG)

The SARS-CoV-2 Antigen Testing pilot study is designed to assess the ability of laboratories to detect SARS-CoV-2 Antigens at clinically relevant levels.

FEATURE	Available Format(s)
<b>Catalogue Number</b>	<b>QAS214224</b>
Number of Challenges	1, 2 or 3
Number of Samples per Challenge	3
Distribution / Testing Period	Q2, Q3 & Q4

### SPECIFICATIONS

**TARGET RANGE** – Covers the clinical range


**MATRIX** – Universal p9 virusPHIX sample stabilisation buffer

**SAMPLE FORMAT** – Eluted swab samples with a buffer

**ANALYSIS TYPE** – Qualitative

**SHIPPING CONDITIONS** – Ambient

**FORMAT** - Liquid ready-to-use





Randox is a non-exclusive distribution partner of QCMD within selected countries. Contact your regional representative or [marketing@randox.com](mailto:marketing@randox.com) for more details.

Copyright © 2021 Randox Laboratories Ltd. All rights Reserved. VAT number: GB 151682708. In EU VAT number: XI 151 6827 08. Product availability may vary from country to country. Some products may be for Research Use Only. For more information on product application and availability, please contact your local Randox Representative.

[marketing@randox.com](mailto:marketing@randox.com) | [randox.com](http://randox.com)